Status:
COMPLETED
Bioequivalency Study of Anastrozole 1 mg Under Fasted Conditions
Lead Sponsor:
Roxane Laboratories
Conditions:
Breast Cancer
Eligibility:
All Genders
18-45 years
Phase:
NA
Brief Summary
The objective of this study was to prove the bioequivalence of Anastrozole Tablet under fasted conditions.
Eligibility Criteria
Inclusion
- No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening
Exclusion
- Positive test for HIV, Hepatitis B, or Hepatitis C.
- Treatment with known enzyme altering drugs.
- History of allergic or adverse response to anastrozole or any comparable or similar product.
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2006
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT01155102
Start Date
April 1 2006
End Date
May 1 2006
Last Update
January 23 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bio-Kinetic Clinical Applications
Springfield, Missouri, United States, 65802